If you have been reading about fatty diacid and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
P7C3-A20 is a synthetic chemical compound belonging to the carbazole class. It was developed as a more potent analog of P7C3. It functions as an activator of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. P7C3-A20 exhibits proneurogenic and neuroprotective properties in preclinical models, crossing the blood-brain barrier and demonstrating efficacy in various models of brain injury and neurodegeneration. Research has investigated its potential to treat Alzheimer's disease, where it reversed pathological features and restored cognitive function in mice. As of 2025, P7C3-A20 remains an experimental compound with no established clinical use in humans.
Every dollar earned is just as valuable to happiness up to a $75,000 annual income, thereafter, the value of each additional dollar earns a diminishing amount of happiness. According to the latest systematic review of the economic literature on life satisfaction, one's perception of their financial circumstances fully mediates the effects of objective circumstances on one's well-being. People overestimate the influence of wealth by 100%. Professor of Economics Richard Easterlin noted that job satisfaction does not depend on salary. In other words, having extra money for luxuries does not increase happiness as much as enjoying one's job or social network. Gilbert is thus adamant, people should go to great lengths to figure out which jobs they would enjoy, and to find a way to do one of those jobs for a living (that is, provided one is also attentive to social ties). Unemployment is detrimental to individual well-being. However, that does not hold true in countries where unemployment is widespread. Psychology Today reports that the impact of unemployment is dampened in those for whom work is less central to their identity, those who receive less criticism and less negative judgments from others, those who can meet their immediate financial obligations and those who do not see their unemployment as high stress and negative. Other protective factors include the expectation of reemployment, routines that structure one's time and evaluating oneself as worthy, competent and successful.
Jean Yee Hwa Yang is an Australian statistician known for her work on variance reduction for microarrays, and for inferring proteins from mass spectrometry data. Yang is a Professor in the School of Mathematics and Statistics at the University of Sydney.
Sources: en.wikipedia.org
=== Francophone Affairs === Mulroney voted in support of the Ford government's September 2018 proposal to use Section 33 of the Canadian Charter of Rights and Freedoms, commonly called the "notwithstanding clause", to overrule a judge's decision that legislation intended to shrink the size of Toronto City Council was in fact in violation of Charter rights. For this position, she faced widespread condemnation from constitutional experts and politicians of all parties, particularly with respect to her duty to ensure the sanctity of the judicial process as Attorney General. In November 2018, Ford announced cuts which included cancelling a "French language university and cut the post of provincial commissioner for French language affairs." Ontario's francophone population represents from 550,000 to 744,000 people in a province of 14 million, according to The New York Times with many concentrated in Sudbury, Ontario, in northern Ontario and near the Ontario-Quebec border in eastern Ontario. The Ford government again came under criticism from the Franco-Ontarian community for its perceived inaction during the 2021 Laurentian University Financial Crisis and its support of the large cuts to the university.
== History == The Celloscope was developed for the Swedish company AB Lars Ljungberg & Co under the direction of engineer Erik Öhlin at Linson Instrument AB. In an interview published in the Clinical Biochemistry in the Nordics, a membership magazine for the Nordic Association for Clinical Chemistry, Lars Ljungberg explains that he and his coworkers had been considering different solutions for counting blood cells for some time when they came across a method presented by the American Navy on how particles could be counted when allowed to pass a capillary hole through which a weak direct current was passed simultaneously. The Celloscope method exploits the feature of blood cells not being conductive and therefore make interruptions (pulses) to the current, which then can be counted. What Ljungberg and coworkers did not know was that Wallace H. Coulter in Chicago had applied for and received a patent on the particle count principle in 1953. When presented at a German tradeshow in September 1957, the Celloscope counter was examined by Dr. George Brecher, the first author of one of the NIH evaluations of the Coulter counter. In a letter to Coulter, Brecher reported about what he thought was a close functional copy of the Coulter counter, yet with simpler electronics and an integrated sample stand, creating a both smaller and less costly instrument for use in clinical applications. When the Celloscope was introduced to the market in the early 60s, a lawsuit was filed by Coulter Electronics Inc. against AB Lars Ljungberg & Co for alleged infringement of the American patent.
R-30490 (also known as 4-methoxymethylfentanyl) is an opioid analgesic related to the highly potent animal tranquilizer carfentanil, and with only slightly lower potency. It was first synthesised by a team of chemists at Janssen Pharmaceutica led by Paul Janssen, who were investigating the structure-activity relationships of the fentanyl family of drugs. R-30490 was found to be the most selective agonist for the μ-opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely related drug sufentanil is widely used for analgesia and anesthesia during major surgery. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
Moreover, not only has bicalutamide been found not to reduce levator ani weight or lean body mass in male rats at doses that are potently antiandrogenic in the prostate, the drug has been found to partially antagonize castration-induced body weight loss and lean body mass loss in male rats. This effect also occurred with JNJ-26146900, a SARM, and with DHT, although neither JNJ-26146900 nor bicalutamide were as effective as DHT at preserving body weight or lean mass. As such, on the basis of such preclinical findings, it has been said that bicalutamide does not have marked antianabolic effects in muscle, and hence shows tissue selectivity in its antiandrogenic actions. Moreover, bicalutamide may also actually activate the AR in muscle to preserve muscle mass. If these findings were to translate to humans, then bicalutamide would inhibit prostate cancer growth without the antiandrogenic muscle atrophy that occurs with castration. Analogously to the animal findings, high-dose bicalutamide monotherapy has been found to preserve lean muscle mass and muscle strength in men with prostate cancer relative to GnRH agonists. Androgens are known to exert direct effects on bone remodeling through activation of ARs in osteoblasts and osteoclasts. In relation to this, androgen deprivation therapy for prostate cancer has been associated with osteopenia. It has been found that bicalutamide monotherapy, in spite of its antiandrogenic activity, does not affect bone remodeling or bone mineral density in healthy male rats.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.